首页|米托蒽醌联合阿糖胞苷、左旋门冬酰胺酶方案诱导21例CD7+急性髓系白血病疗效观察

米托蒽醌联合阿糖胞苷、左旋门冬酰胺酶方案诱导21例CD7+急性髓系白血病疗效观察

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
目的：观察米托蒽醌联合阿糖胞苷及门冬酰胺酶方案对CD7+急性髓系白血病诱导治疗的疗效。方法2008年10月-2013年1月我院收治的原发初治患者CD7+AML21例，予米托蒽醌联合阿糖胞苷及左旋门冬酰胺酶方案进行诱导化疗：米托蒽醌(MTZ)10mg/d，d1-3；阿糖胞苷(Ara-C)200mg/d，d1-7；左旋门冬酰胺酶(L-ASP)10000U/d，qod d8-26。结果21例患者13例获得完全缓解(CR 62%)，3例获得部分缓解(PR 14%)，有效率76%。结论米托蒽醌联合阿糖胞苷及门冬酰胺酶方案作为CD7+急性髓系白血病的诱导化疗方案，疗效尚可，值得进一步研究。
Therapeutic effect of mitoxantrone combined with aclarubicin and asparaginase on twenty-one Cases of CD7+ acute myeloid leukemia
Objective To obersive the effect of remission-inducing regimen on CD7+ acute myeloid leukemia(AML) using mitoxantrone combined with aclarubicin and asparaginase. Methods 21 patients with CD7+ AML were treated with mitoxantrone combined with aclarubicin and asparaginase: mitoxantrone 10mg/d, d1-3; cytarabine 200mg/d, d1-7;asparaginase 10000U, qod d8-26. Results The complete remission rate was 62%; the response rate was 76%. Conclusion Patients may benefit from itoxantrone combined with aclarubicin and asparaginase which would be pay more attention.

LeukemiaAcuteCD7

李红艺、薛民栓、李金星、闫岩

展开 >

451100 河南省新郑市人民医院

白血病 急性 CD7

2013

10.3969/j.issn.1673-5552.2013.17.0004

中国医疗前沿
中国医院协会

中国医疗前沿

影响因子：0.186
ISSN：1673-5552
年,卷(期)：2013.(17)
  • 5